<DOC>
	<DOCNO>NCT01381393</DOCNO>
	<brief_summary>This open label , multi-centre , non-interventional post-marketing surveillance .</brief_summary>
	<brief_title>BONVIVA ( Ibandronate ) PMS ( Post-marketing Surveillance )</brief_title>
	<detailed_description>This open label , multi-centre , non-interventional post-marketing surveillance monitor safety ibandronate administered Korean patient accord prescribe information .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>All subject must satisfy follow criterion study entry : 1 . Subjects diagnose osteoporosis postmenopausal woman . 2 . Subjects investigator believe comply requirement protocol 3 . Subjects experience treatment use ibandronate . 4 . Subjects administered ibandronate normal prescription use Considering nature noninterventional PMS study , strict exclusion criterion set . The doctor participate study enrol subject prescribed ibandronate follow locally approve Prescribing Information . The following criterion check time study entry . According contraindication prescribe information , ibandronate administer follow patient : 1 . Patients know hypersensitivity ibandronate excipients 2 . Uncorrected hypocalcemia 3 . Inability stand sit upright least 60 minute</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>ibandronate</keyword>
</DOC>